Literature DB >> 21091831

Evolving epidemiology of hepatitis C virus.

D Lavanchy1.   

Abstract

More than 20 years after the discovery of the hepatitis C virus (HCV), it is now well established that HCV is of global importance affecting all countries, leading to a major global health problem that requires widespread active interventions for its prevention and control. Chronic hepatitis C was linked to the development of cirrhosis and hepatocellular carcinoma in many areas of the world. Current epidemiological assessments have identified complex patterns with highly variable local prevalence rates between countries and within countries. HCV infection patterns have not significantly changed in most parts of the world since 1997, when first analyzed, partly due to the lack of new and more accurate data. The assessment of the national HCV prevalence and transmission modes should be completed to enable national authorities to prioritize preventive measures and to make the most appropriate use of available resources. The 'patchy' epidemiological situation in some areas will continue to complicate the task of the establishment of global, regional and national base line data. The present assessment finds a global prevalence of 2.35%, affecting 160 million chronically infected individuals. There is an urgent need for more accurate Information on the costs and burden of HCV to society. Twenty-one year after the discovery of HCV, the assessment is far from being complete and little progress has been made in the past 10 years in many countries. In some countries significant increases have been reported and this may also apply to countries were insufficient data exist. A safe and efficient vaccine against HCV is urgently needed.
© 2011 The Author. Clinical Microbiology and Infection © 2011 European Society of Clinical Microbiology and Infectious Diseases.

Entities:  

Mesh:

Year:  2011        PMID: 21091831     DOI: 10.1111/j.1469-0691.2010.03432.x

Source DB:  PubMed          Journal:  Clin Microbiol Infect        ISSN: 1198-743X            Impact factor:   8.067


  432 in total

1.  Serological assay and genotyping of hepatitis C virus in infected patients in zanjan province.

Authors:  Abdolreza Esmaeilzadeh; Maryam Erfanmanesh; Sousan Ghasemi; Farzaneh Mohammadi
Journal:  Hepat Mon       Date:  2014-09-27       Impact factor: 0.660

2.  Hepatitis: New doubts about preventing HAV superinfection in chronic HCV.

Authors:  Daniel Shouval
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2012-05-29       Impact factor: 46.802

3.  Anti-Nuclear Cytoplasmic Antibody-Associated Vasculitis: A Probable Adverse Effect of Sofosbuvir Treatment in Chronic Hepatitis C Patients.

Authors:  Youssef K Ahmad; Salwa Tawfeek; Mohamed Sharaf-Eldin; Hassan E Elbatea; Abdelrahman Kobtan; Ferial El-Kalla; Rehab Badawi; Sherief Abd-Elsalam
Journal:  Hosp Pharm       Date:  2017-04

4.  Health-related quality of life on the clinical course of patients with chronic hepatitis C receiving daclatasvir/asunaprevir therapy: A prospective observational study comparing younger (<70) and elderly (≥70) patients.

Authors:  Kazuki Ohashi; Toru Ishikawa; Mitsuyuki Suzuki; Hiroko Abe; Fujiko Koyama; Tomomi Nakano; Aya Ueki; Hirohito Noguchi; Erina Hasegawa; Shiori Hirosawa; Miki Kobayashi; Hiroshi Hirosawa; Kaede Sato; Takako Fukazawa; Yuka Maruyama; Toshiaki Yoshida
Journal:  Exp Ther Med       Date:  2017-11-10       Impact factor: 2.447

5.  Receipt of alcohol-related care among patients with HCV and unhealthy alcohol use.

Authors:  Mandy D Owens; George N Ioannou; Judith L Tsui; E Jennifer Edelman; Preston A Greene; Emily C Williams
Journal:  Drug Alcohol Depend       Date:  2018-05-08       Impact factor: 4.492

Review 6.  Transfusion transmission of HCV, a long but successful road map to safety.

Authors:  Suganya Selvarajah; Michael P Busch
Journal:  Antivir Ther       Date:  2012-12-07

Review 7.  Genetic variants at the IFNL3 locus and their association with hepatitis C virus infections reveal novel insights into host-virus interactions.

Authors:  Sreedhar Chinnaswamy
Journal:  J Interferon Cytokine Res       Date:  2014-02-20       Impact factor: 2.607

8.  Determining the involvement and therapeutic implications of host cellular factors in hepatitis C virus cell-to-cell spread.

Authors:  Naina Barretto; Bruno Sainz; Snawar Hussain; Susan L Uprichard
Journal:  J Virol       Date:  2014-02-19       Impact factor: 5.103

9.  Robust and persistent replication of the genotype 6a hepatitis C virus replicon in cell culture.

Authors:  Mei Yu; Betty Peng; Katie Chan; Ruoyu Gong; Huiling Yang; William Delaney; Guofeng Cheng
Journal:  Antimicrob Agents Chemother       Date:  2014-02-18       Impact factor: 5.191

10.  Direct-acting antiviral-based triple therapy on alpha-fetoprotein level in chronic hepatitis C patients.

Authors:  Koji Takayama; Norihiro Furusyo; Eiichi Ogawa; Hiroaki Ikezaki; Motohiro Shimizu; Masayuki Murata; Jun Hayashi
Journal:  World J Gastroenterol       Date:  2015-04-21       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.